Crossmark

High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab

Published Online: 2024-08-30

Published Print: 2024-10

Authors

Kim, Jinsoo

Park, Min Seon

Cho, Bum-Joo

Kwon, Soonil https://orcid.org/0000-0003-1543-981X
License Information

Text and Data Mining valid from 2024-08-30

Version of Record valid from 2024-08-30
More Information

Article History

Received: 10 July 2024

Accepted: 13 August 2024

First Online: 30 August 2024

Declarations

:

: Jinsoo Kim, Min Seon Park, Bum-Joo Cho, and Soonil Kwon have nothing to disclose.

: The study was approved by the Institutional Review Board of Hallym University Sacred Heart Hospital (IRB No. Hallym 2024-06-003), and informed consent was waived due to the retrospective nature of the chart review study. The study adhered to the tenets of the Declaration of Helsinki.

Document is current